Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3397 Target Snapshot

Cytochrome P450 2C9 · SINGLE PROTEIN · Homo sapiens

26,603Compounds
3,156Assays
90Approved Drugs
8,346.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P11712. Use UniProt P11712 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P11712 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cytochrome P450 2C9 as ChEMBL target CHEMBL3397, mapped to UniProt P11712. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cytochrome P450 2C9
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3397
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P11712
Cytochrome P450 2C9
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cytochrome P450 2C9 is the right protein anchor across sources, using UniProt P11712 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCytochrome P450 2C9
UniProt AccessionP11712
Component TypeProtein
Sequence Length490 aa

Cytochrome P450 2C9

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Cytochrome P450 2C9, mapped to UniProt P11712. Sequence length is 490 aa.

Mapped IDP11712
Review nameCytochrome P450 2C9
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

90
Approved
26
Phase III
46
Phase II
19
Phase I
Assay Mix

Activity Type Distribution

IC507,307.0
KI1,002.0
EC5036.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL16596 9.3 IC50 0.5 Clinical
CHEMBL220360 9.03 IC50 0.93 Clinical
CHEMBL1825089 9.0 IC50 1.0 Preclinical
CHEMBL38958 9.0 IC50 1.0 Preclinical
CHEMBL1922663 8.82 IC50 1.5 Preclinical
CHEMBL1223034 8.59 IC50 2.6 Preclinical
CHEMBL4593464 8.57 IC50 2.7 Preclinical
CHEMBL1172346 8.52 IC50 3.0 Preclinical
CHEMBL5561914 8.49 IC50 3.2 Preclinical
CHEMBL4557596 8.47 IC50 3.4 Preclinical
Distribution

pChEMBL Value Distribution

996
5.0
517
5.5
337
6.0
132
6.5
68
7.0
24
7.5
12
8.0
4
8.5
4
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

RILPIVIRINE
CHEMBL175691
Approved 2011
ETRAVIRINE
CHEMBL308954
Approved 2008
RIMONABANT
CHEMBL111
Approved 2006
RITONAVIR
CHEMBL163
Approved 1996
FLUVASTATIN
CHEMBL2220442
Approved 1993
NIMODIPINE
CHEMBL1428
Approved 1988
NICARDIPINE
CHEMBL1484
Approved 1988
SULCONAZOLE
CHEMBL1221
Approved 1985
ECONAZOLE
CHEMBL808
Approved 1982
SULFAPHENAZOLE
CHEMBL1109
Approved 1982
DANAZOL
CHEMBL1479
Approved 1976
CLOTRIMAZOLE
CHEMBL104
Approved 1975
MICONAZOLE
CHEMBL91
Approved 1974
TOLBUTAMIDE
CHEMBL782
Approved 1961
TROPICAMIDE
CHEMBL1200604
Approved 1960
DICUMAROL
CHEMBL1466
Approved 1944
Assay Landscape

Assay Landscape

3,157
Total Assays
2,730
Tested Compounds
4
Assay Types
ADME — 3,086 assays, 2,730 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 2,014 1,775 5.3
microsome format 614 620 5.3
assay format 256 239 5.3
cell-based format 136 38 5.1
tissue-based format 61 58 5.7
cell membrane format 4 0
subcellular format 1 0
Binding — 69 assays, 265 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 32 118 5.2
assay format 21 70 5.0
tissue-based format 10 26 5.0
microsome format 5 1 5.0
cell-based format 1 50 5.9
Functional — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0
Toxicity — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
microsome format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine